# US 2014/0193403 A1 · Epitopes of IL-17A and IL-17F and Antibodies Specific Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193403 A1
- Document ID: US20140193403A1
- Status: Published application
- Kind: A1
- Application number: 14/173,613
- Filed: 2014-02-05
- Published: 2014-07-10
- Earliest claimed: 2008-04-23
- Assignees: UCB Pharma S.A.
- Applicants: UCB Pharma S.A.
- Inventors: Thomas Allen Ceska; Alistar James Henry; Jiye Shi
- Web page: https://patentgrep.com/patent/US20140193403A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- C07K 14/54: Interleukins [IL]
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.

## Claims

### Claim 1

(canceled)

### Claim 2

A chimeric or humanised antibody that specifically binds an epitope of human IL-17F, wherein the epitope comprises residues GLN71, CYS72, ILE86, ASN89, SER90 and VAL128 of SEQ ID NO:22.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the epitope comprises residues GLN71, CYS72, ASN74, LEU75, ILE86, ASN89, SER90, PRO92, VAL128, HIS131 and GLN133 of SEQ ID NO:22.

### Claim 4 (depends on 2)

The antibody of claim 2, wherein the epitope comprises one or more of the residues selected from the group consisting of GLN71, CYS72, ILE86, ASN89, SER90 and VAL128 of SEQ ID NO:22.

### Claim 5 (depends on 2)

A composition comprising the antibody of claim 2 and a pharmaceutically acceptable excipient.

### Claim 6 (depends on 2)

The antibody of claim 2, which has binding affinity for human IL-17F of 500 pM or less.

### Claim 7

A monoclonal antibody that specifically binds an epitope of human IL-17F, wherein the epitope comprises residues GLN71, CYS72, ILE86, ASN89, SER90 and VAL128 of SEQ ID NO:22 and wherein the monoclonal antibody additionally binds IL-17A.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the epitope comprises residues GLN71, CYS72, ASN74, LEU75, ILE86, ASN89, SER90, PRO92, VAL128, HIS131 and GLN133 of SEQ ID NO:22.